See attached document. Signum’s scientists have published a review on the drug ability of PP2A for Alzheimer’s disease, further supporting the value and potential of our approaches. This review brings together a wealth of data demonstrating the safe and efficacious targeting of this critical enzyme whose activity is compromised in disease.
Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease. Future Med Chem. 2011 May; 3(7):821-33.